Plain-English translation of NCT06126016 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study designed to track how well Pacitol Injection (paricalcitol) works and how safe it is for people with stage 5D chronic kidney disease—the most advanced form—who are on hemodialysis and have developed a condition where their parathyroid glands overact. Researchers will monitor patients already scheduled to receive this medication according to standard medical practice, rather than assigning them to it as part of the trial.
Even though this medication is already in use, researchers want to gather real-world information about how well the medication controls the parathyroid condition in a larger group of patients and whether any safety concerns arise during routine treatment.
You likely qualify if…
You likely don't qualify if…
You would continue receiving Pacitol Injection as your doctor has already prescribed it. Researchers will track your progress through regular clinic visits and medical records—gathering information about how well the medication controls your parathyroid condition and whether you experience any side effects. The study expects to enroll about 1,000 patients total across multiple dialysis centers and follow them over time.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~1,000 participants
Started
October 2023
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shinyoung Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.